Substance P Neurokinin 1 Receptor Activation within the Dorsal Raphe Nucleus Controls Serotonin Release in the Mouse Frontal Cortex

• Published in: Molecular pharmacology Vol. 72; no. 6; pp. 1411 - 1418
• Main Authors: Guiard, Bruno P., Guilloux, Jean-Philippe, Reperant, Christelle, Hunt, Stephen P., Toth, Miklos, Gardier, Alain M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2007; American Society for Pharmacology and Experimental Therapeutics
• Subjects: Animals; Frontal Lobe - metabolism; Injections, Intraventricular; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Raphe Nuclei - drug effects; Raphe Nuclei - metabolism; Raphe Nuclei - physiology; Receptors, Neurokinin-1 - metabolism; Receptors, Neurokinin-1 - physiology; Serotonin - metabolism; Substance P - administration & dosage; Substance P - metabolism; Substance P - physiology
• ISSN: 0026-895X; 1521-0111; 1521-0111
• DOI: 10.1124/mol.107.040113

Preclinical studies suggest that substance P (SP) neurokinin 1 (NK1) receptor antagonists are efficient in the treatment of anxiety and depression. This therapeutic activity could be mediated via stimulation of serotonin (5-HT) neurons located in the dorsal raphe nucleus (DRN), which receive important SP-NK1 receptor immunoreactive innervations. The present study examined the effects of intraraphe injection of SP on extracellular 5-HT levels in the frontal cortex, ventral hippocampus, and DRN by using intracerebral microdialysis in conscious mice. Intraraphe SP injection dose dependently decreased cortical 5-HT release, whereas no effects were detected in the ventral hippocampus. Cortical effects were blocked by the selective NK1 receptor antagonist N-[[2-methoxy-5-[5-(trifluoromethyl)tetrazol-1-yl]phenyl]methyl]-2-phenylpiperidin-3-amine (GR205171) and completely dampened in mice lacking NK1 receptors. Furthermore, genetic (in knockout 5-HT1A-/- mice) or pharmacological inactivation of 5-HT1A autoreceptors blocked cortical responses to SP. Contrasting with its cortical effects, intraraphe SP injection increased 5-HT outflow in the DRN in wild-type mice; this effect was potentiated by a local perfusion of the selective 5-HT1A antagonist N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide (WAY100635). Finally, SP-induced changes in frontal cortex and DRN dialysate 5-HT levels were blocked by the DRN perfusion of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate ionotropic receptor antagonist 6,7-dinitroquinoxaline-2,3-dione (DNQX). These data support the hypothesis that SP-induced over-activation of 5-HT1A autoreceptors within the DRN limits cortical 5-HT release. A better knowledge of the complex relationship between tachykininergic, serotonergic, and glutamatergic systems within the DRN might help better understand the pathophysiology and subsequent treatment of depression.